Eligibility depends on BMI criteria and clinical suitability
Its important to let your patients know as they will often blame the last medicine given on any negative effects
"We expect all of them to take note of what could be the potential consequences of their continued behavior." Why did Novo Nordisk sue now
Abbreviations GCGR: Glucagon receptor GIP: Glucose-dependent insulinotropic polypeptide GIPR: Glucose-dependent insulinotropic polypeptide receptor GLP-1: Glucagon-like peptide-1 GLP-1R: Glucagon-like peptide-1 receptor NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis STEP: Semaglutide Treatment Effect in People with Obesity References Bray GA, Kim KK, Wilding JPH (2017) Obesity: a chronic relapsing progressive disease process
Yes, semaglutide may cause some side effects, but they typically fade after a few weeks
[DOI] [PMC free article] [PubMed] [Google Scholar] 63.Afzaal M., Saeed F., Shah Y.A., Hussain M., Rabail R., Socol C.T., Hassoun A., Pateiro M., Lorenzo J.M., Rusu A.V., et al